Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 210

Similar articles for PubMed (Select 14745704)

1.

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E.

J Infect Dis. 2004 Feb 1;189(3):462-70. Epub 2004 Jan 20.

2.

Safety and immunogenicity of an intranasal sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

Adderson E, Branum K, Sealy RE, Jones BG, Surman SL, Penkert R, Freiden P, Slobod KS, Gaur AH, Hayden RT, Allison K, Howlett N, Utech J, Allay J, Knight J, Sleep S, Meagher MM, Russell CJ, Portner A, Hurwitz JL.

Clin Vaccine Immunol. 2015 Mar;22(3):298-303. doi: 10.1128/CVI.00618-14. Epub 2014 Dec 31.

PMID:
25552633
3.

Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.

Malkin E, Yogev R, Abughali N, Sliman J, Wang CK, Zuo F, Yang CF, Eickhoff M, Esser MT, Tang RS, Dubovsky F.

PLoS One. 2013 Oct 29;8(10):e77104. doi: 10.1371/journal.pone.0077104. eCollection 2013.

4.

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group.

Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5.

5.

Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine.

Yang CF, Wang CK, Malkin E, Schickli JH, Shambaugh C, Zuo F, Galinski MS, Dubovsky F; Study Group, Tang RS.

Vaccine. 2013 Jun 10;31(26):2822-7. doi: 10.1016/j.vaccine.2013.04.006. Epub 2013 Apr 16.

PMID:
23602668
6.

Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.

Mason JN, Elbahesh H, Russell CJ.

J Virol. 2013 May;87(10):5959-69. doi: 10.1128/JVI.00227-13. Epub 2013 Mar 20.

7.

State of the art: Could nursing mothers be vaccinated with attenuated live virus vaccine?

Alain S, Dommergues MA, Jacquard AC, Caulin E, Launay O.

Vaccine. 2012 Jul 13;30(33):4921-6. doi: 10.1016/j.vaccine.2012.05.047. Epub 2012 May 31. Review.

PMID:
22659446
8.

Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC.

Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14.

9.

Viral interference induced by live attenuated virus vaccine (OPV) can prevent otitis media.

Seppälä E, Viskari H, Hoppu S, Honkanen H, Huhtala H, Simell O, Ilonen J, Knip M, Hyöty H.

Vaccine. 2011 Nov 3;29(47):8615-8. doi: 10.1016/j.vaccine.2011.09.015. Epub 2011 Sep 20.

PMID:
21939720
10.

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.

Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F; MI-CP149 Investigators.

Pediatr Infect Dis J. 2012 Feb;31(2):109-14. doi: 10.1097/INF.0b013e31823386f1.

PMID:
21926667
11.

Progress in the development of human parainfluenza virus vaccines.

Schmidt AC, Schaap-Nutt A, Bartlett EJ, Schomacker H, Boonyaratanakornkit J, Karron RA, Collins PL.

Expert Rev Respir Med. 2011 Aug;5(4):515-26. doi: 10.1586/ers.11.32. Review.

12.

The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.

Karron RA, Casey R, Thumar B, Surman S, Murphy BR, Collins PL, Schmidt AC.

Pediatr Infect Dis J. 2011 Oct;30(10):e186-91. doi: 10.1097/INF.0b013e31822ea24f.

13.

A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants.

Bernstein DI, Falloon J, Yi T.

Vaccine. 2011 Sep 16;29(40):7042-8. doi: 10.1016/j.vaccine.2011.07.031. Epub 2011 Jul 22.

PMID:
21782874
14.

The role of non-human primates in the neurological safety of live viral vaccines (review).

Levenbook I.

Biologicals. 2011 Jan;39(1):1-8. doi: 10.1016/j.biologicals.2010.11.003. Epub 2010 Dec 22. Review.

PMID:
21183358
15.

Bovine parainfluenza-3 virus.

Ellis JA.

Vet Clin North Am Food Anim Pract. 2010 Nov;26(3):575-93. doi: 10.1016/j.cvfa.2010.08.002. Review.

PMID:
21056802
16.

Reactogenicity and immunogenicity of a live-attenuated refrigerator-stable varicella vaccine (OKA strain) in healthy seronegative subjects age 10 months to 12 years.

Hadinegoro SR, Hindra IS, Han HH, Gatchalian S, Bock HL.

Southeast Asian J Trop Med Public Health. 2009 Sep;40(5):991-9.

PMID:
19842382
17.

Seasonal influenza vaccines.

Fiore AE, Bridges CB, Cox NJ.

Curr Top Microbiol Immunol. 2009;333:43-82. doi: 10.1007/978-3-540-92165-3_3. Review.

PMID:
19768400
19.

Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.

Valera R, García HM, Jidy MD, Mirabal M, Armesto MI, Fando R, García L, Fernández R, Año G, Cedré B, Ramírez M, Bravo L, Serrano T, Palma S, González D, Miralles F, Medina V, Nuñez F, Plasencia Y, Martínez JC, Mandarioti A, Lugones J, Rodríguez BL, Moreno A, González D, Baro M, Solis RL, Sierra G, Barbera R, Domínguez F, Gutiérrez C, Kouri G, Campa C, Menéndez J.

Vaccine. 2009 Nov 5;27(47):6564-9. doi: 10.1016/j.vaccine.2009.08.042. Epub 2009 Aug 29.

PMID:
19720365
20.

Comparison of single vaccination versus revaccination with a modified-live virus vaccine containing bovine herpesvirus-1, bovine viral diarrhea virus (types 1a and 2a), parainfluenza type 3 virus, and bovine respiratory syncytial virus in the prevention of bovine respiratory disease in cattle.

Step DL, Krehbiel CR, Burciaga-Robles LO, Holland BP, Fulton RW, Confer AW, Bechtol DT, Brister DL, Hutcheson JP, Newcomb HL.

J Am Vet Med Assoc. 2009 Sep 1;235(5):580-7. doi: 10.2460/javma.235.5.580.

PMID:
19719452
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk